Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP181031.RAQtUklX2WKCozB0z-HIaydjlqoiy2I8Rff7Rh6vd0Wak130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP181031.RAQtUklX2WKCozB0z-HIaydjlqoiy2I8Rff7Rh6vd0Wak130_assertion type Assertion NP181031.RAQtUklX2WKCozB0z-HIaydjlqoiy2I8Rff7Rh6vd0Wak130_head.
- NP181031.RAQtUklX2WKCozB0z-HIaydjlqoiy2I8Rff7Rh6vd0Wak130_assertion wasGeneratedBy ECO_0000203 NP181031.RAQtUklX2WKCozB0z-HIaydjlqoiy2I8Rff7Rh6vd0Wak130_provenance.
- NP181031.RAQtUklX2WKCozB0z-HIaydjlqoiy2I8Rff7Rh6vd0Wak130_assertion wasDerivedFrom befree-20140225 NP181031.RAQtUklX2WKCozB0z-HIaydjlqoiy2I8Rff7Rh6vd0Wak130_provenance.
- NP181031.RAQtUklX2WKCozB0z-HIaydjlqoiy2I8Rff7Rh6vd0Wak130_assertion SIO_000772 22279054 NP181031.RAQtUklX2WKCozB0z-HIaydjlqoiy2I8Rff7Rh6vd0Wak130_provenance.
- NP181031.RAQtUklX2WKCozB0z-HIaydjlqoiy2I8Rff7Rh6vd0Wak130_assertion evidence source_evidence_literature NP181031.RAQtUklX2WKCozB0z-HIaydjlqoiy2I8Rff7Rh6vd0Wak130_provenance.
- NP181031.RAQtUklX2WKCozB0z-HIaydjlqoiy2I8Rff7Rh6vd0Wak130_assertion description "[These agents, including the Bruton tyrosine kinase (BTK) inhibitor PCI-32765, display an unexpected response in patients with chronic lymphocytic leukemia (CLL): a rapid and sustained reduction of lymphadenopathy accompanied by transient lymphocytosis, which is reversible upon temporary drug deprivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP181031.RAQtUklX2WKCozB0z-HIaydjlqoiy2I8Rff7Rh6vd0Wak130_provenance.